Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 23 trials

Success Rate

100.0%

+13.4% vs industry average

Late-Stage Pipeline

13%

3 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

9 recruiting

Enrollment Performance

Analytics

N/A
8(42.1%)
Phase 2
7(36.8%)
Phase 4
2(10.5%)
Early Phase 1
1(5.3%)
Phase 3
1(5.3%)
19Total
N/A(8)
Phase 2(7)
Phase 4(2)
Early Phase 1(1)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (23)

Showing 20 of 23 trials
NCT05987826Phase 2Recruiting

Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC

Role: collaborator

NCT07272499Phase 2Recruiting

Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease

Role: collaborator

NCT07135310Not ApplicableRecruiting

STROKE 120 ACTION Trial

Role: lead

NCT07634861Not ApplicableRecruiting

Evaluating a Text-Prompt AI Assistant for Chest CT Scans (AI-REPORT Study)

Role: collaborator

NCT07446452Phase 2Recruiting

Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

Role: collaborator

NCT05761912Active Not Recruiting

Application of Ultrasound Radiomics in Ultrasound Fusion Targeted Prostate Biopsy

Role: lead

NCT06085690Not ApplicableRecruiting

Multicenter Clinical Translational Study of "ICU-NO CRBSI" Based on Improvement Science

Role: collaborator

NCT06983275Not ApplicableRecruiting

Exploration of the Effectiveness of Vibrational Intervention in Improving Insomnia Symptoms

Role: collaborator

NCT07065435Phase 2Recruiting

RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

Role: collaborator

NCT03764241Phase 3Unknown

Treatment of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant

Role: collaborator

NCT04033861Phase 4Unknown

Early rhBNP on Myocardial Remodeling and Reperfusion in Patients With STEMI

Role: collaborator

NCT05001113Not ApplicableCompleted

Surgery for Masaoka-Koga I-II Thymoma

Role: collaborator

NCT04973306Phase 2Recruiting

Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC

Role: collaborator

NCT05318391Completed

Translational Study of Molecular Classification of Relapsed/Refractory Diffuse Large B-cell Lymphoma

Role: collaborator

NCT05141617Not ApplicableUnknown

Management of Oxaliplatin-related Gastroesophageal Variceal Bleeding

Role: collaborator

NCT05069194Unknown

Study on the Etiology, Risk Factors and Pathogenesis of COPD Based on Clinical Bioinformatics

Role: collaborator

NCT04486430Phase 2Completed

Efficacy and Safety Study of Neu2000KWL for Acute Ischemic Stroke Patients Within 6 Hours of Onset

Role: collaborator

NCT02897713Not ApplicableSuspended

Feasibility, Safety, and Outcomes of Intensive Enteral Nutrition in Patients With Mechanical Ventilation

Role: collaborator

NCT02303730Phase 4Completed

Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes

Role: collaborator

NCT03030508Unknown

Discovery and Validate of Multi-genetic Biomarkers for Capecitabine in Chinese Colorectal Patients

Role: collaborator